The role of ¹⁸F-FDG PET/CT in Better Follow up in Patient with Hodgkin Lymphoma: A Case Report

Mehrdad Payandeh¹, Mehrnoosh Aeinfar¹, Masoud Sadeghi² and Edris Sadeghi^3,

¹Department of Hematology and Medical Oncology, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran

³Department of Nursing, Borujerd Branch, Islamic Azad University, Borujerd, Iran

Cite this paper:
Mehrdad Payandeh, Mehrnoosh Aeinfar, Masoud Sadeghi and Edris Sadeghi. The role of ¹⁸F-FDG PET/CT in Better Follow up in Patient with Hodgkin Lymphoma: A Case Report. American Journal of Cancer Prevention. 2017; 5(3):41-43. doi: 10.12691/ajcp-5-3-5

Abstract

PET/CT scans have recently become the gold standard in determining the extent of HL, with a specificity and sensitivity that is superior to that of CT scans alone. Herein, we survey relationship between PET/CT with follow up in Hodgkin disorder. On November 14, 2016, for 36 years old man with complaint of mass sensation with radicalular neck pain, sonography in the axillary right region was done and in report multiple lymph nodes with cortical thickening and hilar obliteration. In complementary IHC that was done in other center CD 10, Ki67, CD 5, CD 21 and CD 23 were negative and CD 68, Pax5, CD 3 were positive. Low dose CT images (30 mAs and 120 KV) without contrast were obtained for attenuation correction and anatomical localization purposes showed Hodgkin's lymphoma with initial staging (metabolically active conglomerated nodal disease in the left axillary region accompanied by a suspicious focal involvement of the spleen PET/CT images can be a very useful guide for a doctor and, in part, to exclude a patient and his/her family from psychological feedback in order to get the right decision.

Keywords:
CD hodgkin lymphoma PET/CT

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

Figures

References:

[1]	Payandeh M, Sadeghi M, Sadeghi E. Maintenance Therapy with Procarbazin and Chlorambucil without Autologous Stem Cell Transplantation as a New Option for Patient with Hodgkin Lymphoma. Sch. J. App. Med. Sci. 2015; 3(1E): 363-366.
[2]	Non-Hodgkin lymphoma. American Cancer Society Web site. Available at: http://www.cancer.org/acs/groups/cid/documents/webcontent/003126-pdf.pdf. Published October 25, 2010. Accessed May 20, 2011.
[3]	Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of biopsy and PET/CT results. Annals of Oncology. 2002; 13(3): 490-1.
[4]	Gota VS, Purandare NC, Gujral S, Shah S, Nair R, Rangarajan V. Positron emission tomography/computerized tomography evaluation of primary Hodgkin's disease of liver. Indian J Cancer. 2009; 46(3): 237-9.
[5]	Hutchings M., Loft A., Hansen M. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma. Haematologica. 2006; 91: 482-489.
[6]	Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med. 2006; 47: 1326-1334.
[7]	Cheson BD, Fisher RI, Barrington SF, et al; Alliance, Australasian Leukaemia and Lymphoma. Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/ Dutch Hemato-Oncology Group; Grupo Espan˜ol de Me´dula O´ sea; German High-Grade Lymphoma Study Group; German Hodgkin’s Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27): 3059-3068.
[8]	Procedure Manual: PET/CT Scan Tumor Imaging. Boston, MA: Beth Israel Deaconess Medical Center, Division of Nuclear Medicine; 2008.
[9]	Podoloff DA, Macapinlac HA. PET and PET/CT in management of the lymphomas. Radiol Clin North Am. 2007; 45: 689-696.
[10]	Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nucl Med. 2006; 47: 1326-1334.
[11]	Allen-Auerbach M, de Vos S, Czernin J. The impact of fluorodeoxyglucose positron emission tomography in primary staging and patient management in lymphoma patients. Radiol Clin North Am. 2008; 46: 199-211.